The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability - PubMed

Affiliations

• PMID: 20395317
• DOI: 10.1177/0269881110367445

Clinical Trial

The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability

Robin L Carhart-Harris et al. J Psychopharmacol. 2011 Nov.

Abstract

This study sought to assess the tolerability of intravenously administered psilocybin in healthy, hallucinogen-experienced volunteers in a mock-magnetic resonance imaging environment as a preliminary stage to a controlled investigation using functional magnetic resonance imaging to explore the effects of psilocybin on cerebral blood flow and activity. The present pilot study demonstrated that up to 2 mg of psilocybin delivered as a slow intravenous injection produces short-lived but typical drug effects that are psychologically and physiologically well tolerated. With appropriate care, this study supports the viability of functional magnetic resonance imaging work with psilocybin.

Similar articles

• Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.

  Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX. Kraehenmann R, et al. Biol Psychiatry. 2015 Oct 15;78(8):572-81. doi: 10.1016/j.biopsych.2014.04.010. Epub 2014 Apr 26. Biol Psychiatry. 2015. PMID: 24882567 Clinical Trial.

• A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment.

  Turton S, Nutt DJ, Carhart-Harris RL. Turton S, et al. Curr Drug Abuse Rev. 2014;7(2):117-27. doi: 10.2174/1874473708666150107120930. Curr Drug Abuse Rev. 2014. PMID: 25563444 Clinical Trial.

• Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow.

  Lewis CR, Preller KH, Kraehenmann R, Michels L, Staempfli P, Vollenweider FX. Lewis CR, et al. Neuroimage. 2017 Oct 1;159:70-78. doi: 10.1016/j.neuroimage.2017.07.020. Epub 2017 Jul 12. Neuroimage. 2017. PMID: 28711736 Clinical Trial.

• [The impact of psilocybin on visual perception and spatial orientation--neuropsychological approach].

  Jastrzebski M, Bala A. Jastrzebski M, et al. Psychiatr Pol. 2013 Nov-Dec;47(6):1157-67. Psychiatr Pol. 2013. PMID: 25007546 Review. Polish.

• Psilocybin--summary of knowledge and new perspectives.

  Tylš F, Páleníček T, Horáček J. Tylš F, et al. Eur Neuropsychopharmacol. 2014 Mar;24(3):342-56. doi: 10.1016/j.euroneuro.2013.12.006. Epub 2013 Dec 17. Eur Neuropsychopharmacol. 2014. PMID: 24444771 Review.

Cited by

• The central role of the Thalamus in psychosis, lessons from neurodegenerative diseases and psychedelics.

  Onofrj M, Russo M, Delli Pizzi S, De Gregorio D, Inserra A, Gobbi G, Sensi SL. Onofrj M, et al. Transl Psychiatry. 2023 Dec 13;13(1):384. doi: 10.1038/s41398-023-02691-0. Transl Psychiatry. 2023. PMID: 38092757 Free PMC article. Review.

• Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.

  Galvão-Coelho NL, Marx W, Gonzalez M, Sinclair J, de Manincor M, Perkins D, Sarris J. Galvão-Coelho NL, et al. Psychopharmacology (Berl). 2021 Feb;238(2):341-354. doi: 10.1007/s00213-020-05719-1. Epub 2021 Jan 11. Psychopharmacology (Berl). 2021. PMID: 33427944 Free PMC article. Review.

• The Health and Clinical Benefits of Medicinal Fungi.

  Hobbs C. Hobbs C. Adv Biochem Eng Biotechnol. 2023;184:285-356. doi: 10.1007/10_2023_230. Adv Biochem Eng Biotechnol. 2023. PMID: 37468715

• The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.

  Rosenblat JD, Husain MI, Lee Y, McIntyre RS, Mansur RB, Castle D, Offman H, Parikh SV, Frey BN, Schaffer A, Greenway KT, Garel N, Beaulieu S, Kennedy SH, Lam RW, Milev R, Ravindran AV, Tourjman V, Ameringen MV, Yatham LN, Taylor V. Rosenblat JD, et al. Can J Psychiatry. 2023 Jan;68(1):5-21. doi: 10.1177/07067437221111371. Epub 2022 Aug 17. Can J Psychiatry. 2023. PMID: 35975555 Free PMC article. Review.

• LSD enhances suggestibility in healthy volunteers.

  Carhart-Harris RL, Kaelen M, Whalley MG, Bolstridge M, Feilding A, Nutt DJ. Carhart-Harris RL, et al. Psychopharmacology (Berl). 2015 Feb;232(4):785-94. doi: 10.1007/s00213-014-3714-z. Epub 2014 Sep 23. Psychopharmacology (Berl). 2015. PMID: 25242255

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database